Optimizerx CORP Form 4 insider transactions

OptimizeRx Corp. reports that Director Cathy Klema acquired 34,517 shares of common stock on June 9, 2026, through a grant of restricted stock units.

OptimizeRx Corp director James Paul Lang acquired 34,517 shares of common stock through a restricted stock unit grant.

OptimizeRx Corp. reports a Form 4 filing detailing a director's acquisition of restricted stock units.

OptimizeRx Corp. reports a grant of restricted stock units to Director Patrick D. Spangler, vesting in one year or at the next annual meeting.

OptimizeRx Corp. reports a grant of restricted stock units to Director Ellen O'Connor Vos.

OptimizeRx Corp. reports that Director Gregory D. Wasson was granted restricted stock units (RSUs) on June 9, 2026, vesting on the earlier of the first anniversary of the grant or the company's next annual meeting.

OptimizeRx Corp reports a Form 4 filing detailing a director's acquisition of 13,060 shares of common stock.

OptimizeRx Corp's Chief Commercial Officer, Theresa Greco, reported a disposition of company shares on May 15, 2026, primarily to cover tax obligations upon the vesting of restricted stock units.

OptimizeRx Corp CEO Stephen L. Silvestro disposed of 5,219 shares of common stock to cover tax obligations upon the vesting of restricted stock units.

OptimizeRx's Chief Legal & Admin Officer, Marion Odence-Ford, acquired common stock through RSU conversion and sold shares to cover tax obligations.

OptimizeRx CEO Stephen L. Silvestro filed an amended Form 4 to clarify a stock disposition related to tax withholding on restricted stock units.

OptimizeRx Chief Commercial Officer Theresa Greco disposed of 1,420 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx Corp's CEO, Stephen L. Silvestro, disposed of 3,361 common shares at $12.74 each to cover tax obligations from restricted stock unit vesting.

OptimizeRx's Chief Legal & Admin Officer, Marion Odence-Ford, reported a future disposition of 4,051 shares for tax withholding related to restricted stock unit vesting.

OptimizeRx's Chief Product & Tech Officer, Doug Besch, disposed of 4,079 common shares at $12.74 each to cover tax withholding obligations from RSU vesting.

OptimizeRx's Chief Finance & Strategy Officer, Edward Stelmakh, disposed of 3,658 shares of common stock at $12.74 per share to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx's Chief Finance & Strategy Officer, Edward Stelmakh, filed an amended Form 4 to correct the transaction code for shares withheld for tax obligations.

OptimizeRx's Chief Finance & Strategy Officer, Edward Stelmakh, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

OptimizeRx CEO Stephen L. Silvestro reported the acquisition of common stock from RSU conversion and a related tax withholding disposition.

OptimizeRx's Chief Legal & Admin Officer, Marion Odence-Ford, acquired common stock through RSU vesting and subsequently sold shares to cover tax obligations.

OptimizeRx Chief Operating Officer Brendan W. Merrell reported the disposition of 289 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx Chief Business Officer Andrew J. D'Silva disposed of 703 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx's Chief Product & Tech Officer, Doug Besch, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

OptimizeRx Chief Operating Officer Brendan W. Merrell disposed of 712 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx Chief Business Officer Andrew J. D'Silva disposed of 868 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx Chief Operating Officer Brendan W. Merrell reported the acquisition of restricted stock units and stock options, alongside a disposition of shares for tax obligations.

OptimizeRx Chief Business Officer Andrew J. D'Silva disposed of shares to cover tax withholding obligations on October 1 and October 3, 2025.

OptimizeRx Chief Commercial Officer Theresa Greco disposed of 1,693 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx's Chief Legal & Admin Officer, Marion Odence-Ford, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

OptimizeRx CEO Stephen L. Silvestro converted restricted stock units into common shares and sold a portion to cover tax obligations.